Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

CanSino Biologics: Clinical Trials & FDA Approval Profile

CanSino Biologics (Global / Institutional) sponsors 21 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (1 recruiting now), 11 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)14.3%
Median Closed Enrollment vs National (145 pts)840 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for CanSino Biologics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)21
Active Pipeline (Recruiting Now)6 (1)
Completed vs Stopped Early11 / 3 (14.3%)
Median Closed Actual Enrollment840 participants
Physical Hospital Site Disclosure98.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the CanSino Biologics Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI